Millions of individuals in the United States require long-term treatment with an oral
anticoagulant. For decades, vitamin K antagonists were the only oral option available; …

Direct oral anticoagulants (DOACs) are a more manageable alternative than vitamin K
antagonists (VKAs) to prevent stroke in patients with nonvalvular atrial fibrillation and to …

Ciraparantag, an anticoagulant reversal agent, is a small molecule specifically designed to
bind noncovalently by charge-charge interaction to unfractionated heparin and low …

Aim: To compare the safety and efficacy of direct oral anticoagulants (DOAC) relative to
vitamin K antagonists (VKA) for the treatment of left ventricular thrombus (LVT). Methods …

Background In patients on anticoagulant treatment, the major bleeding (MB) definition
released by the International Society of Thrombosis and Haemostasis (ISTH) is widely …

Background Nursing home residents with atrial fibrillation are at high risk for ischemic stroke
and bleeding events. The most recent national estimate (2004) indicated less than one third …

Left ventricular (LV) thrombus is a complication of acute endomyocardial injury and chronic
ventricular wall hypokinesis, resulting in increased risk of thromboembolic complications …

Abstract Background Direct oral anticoagulants (DOACs) interfere with lupus anticoagulant
(LAC) testing. DOAC‐Stop (D‐S) represents a preanalytical strategy to cope with this issue …

Purpose Although direct oral anticoagulants (DOACs) are associated with an overall
favourable safety profile, the risk of gastrointestinal bleeding with DOACs compared with …

Older people, are underrepresented in randomised controlled trials of direct oral
anticoagulants (DOACs) for stroke prevention in atrial fibrillation (AF). The aim of this study …